US4474804A
Expired / Lapsed
US
⏱️ 0.0 years remaining
7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives useful as cardiovascular agents
Assignee: ER Squibb and Sons LLC
•
Filing: 1983-09-19
•
Granted: 1984-10-02
•
Expires: 2003-09-19
Abstract
Abstract 7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.
Inventors
- 👤 Jagabandhu Das
- 👤 Martin F. Haslanger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 01:45
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/08; A; A61; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
106 words
A compound having the structural formula ##STR18## and including all stereoisomers thereof, wherein; R is H, lower alkyl or alkali metal; A is --CH═CH--, or (CH 2 ) 2 ; R 1 is lower alkyl, aryl-lower alkyl, aryl, cycloalkyl or cycloalkylalkyl; m is 0 or 1 and n is 0 or 1; wherein the term "aryl" used by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion and the term "cycloalkyl" used by itself or as part of another group refers to saturated cyclic hydrocarbon groups containing 3 to 12 carbons.
Claim 2
Dependent Claim
106 words
A compound having the structural formula ##STR18## and including all stereoisomers thereof, wherein; R is H, lower alkyl or alkali metal; A is --CH═CH--, or (CH 2 ) 2 ; R 1 is lower alkyl, aryl-lower alkyl, aryl, cycloalkyl or cycloalkylalkyl; m is 0 or 1 and n is 0 or 1; wherein the term "aryl" used by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion and the term "cycloalkyl" used by itself or as part of another group refers to saturated cyclic hydrocarbon groups containing 3 to 12 carbons.
Claim 3
Dependent Claim
11 words
The compound as defined in claim 1 wherein A is --CH═CH.
Claim 4
Dependent Claim
12 words
The compound as defined in claim 1 wherein R 1 is cycloalkyl.
Claim 5
Dependent Claim
13 words
The compound as defined in claim 1 wherein --COOR is in the meta-position.
Claim 6
Dependent Claim
11 words
The compound as defined in claim 1 wherein R is H.
Claim 7
Dependent Claim
15 words
The compound as defined in claim 1 wherein A is (CH 2 ) 2 .
Claim 8
Dependent Claim
21 words
The compound as defined in claim 1 wherein R 1 is cyclohexyl, A is --CH═CH-- and COOR is in the meta-position.
Claim 9
Dependent Claim
15 words
The compound as defined in claim 1 wherein m is 1 and n is 0.
Claim 10
Dependent Claim
21 words
The compound as defined in claim 1 having the name [1β,2α(Z),3α(1E),4β]-3-[3-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-1-propenyl]benzoic acid or its methyl ester, including all isomers of each.
Claim 11
Dependent Claim
21 words
The compound as defined in claim 1 having the name [1β,2α(E),3α(1E),4β]-3-[3-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-1-propenyl]benzoic acid or its methyl ester, including all isomers of each.
Claim 12
Dependent Claim
30 words
A method of inhibiting platelet aggregation which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
30 words
A composition for inhibiting platelet aggregation comprising an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
Claim 14
Dependent Claim
26 words
The method as defined in claim 11 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
References Cited (Backward Citations)
US4143054A
Cited
US4187236A
Cited
US4220594A
Cited
US4254044A
Cited
GB2039909A
Cited
US4228180A
Cited
EP0043292A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-10-02 | 1988-04-02 | 1988-10-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-10-02 | 1992-04-02 | 1992-10-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-10-02 | 1996-04-02 | 1996-10-02 | $7700.00 | Window Closed / Lapsed |